Literature DB >> 11731024

Conditional gene targeting for cancer gene therapy.

Y S Haviv1, D T Curiel.   

Abstract

Current treatment of solid tumors is limited by severe adverse effects, resulting in a narrow therapeutic index. Therefore, cancer gene therapy has emerged as a targeted approach that would significantly reduce undesired side effects in normal tissues. This approach requires a clear understanding of the molecular biology of both the malignant clone and the biological vectors that serve as vehicles to target cancer cells. In this review we discuss novel approaches for conditional gene expression in cancer cells. Targeting transgene expression to malignant tissues requires the use of specific regulatory elements including promoters based on tumor biology, tissue-specific promoters and inducible regulatory elements. We also discuss the regulation of both replication and transgene expression by conditionally-replicative viruses. These approaches have the potential to restrict the expression of transgenes exclusively to tissues of interest and thereby to increase the therapeutic index of future vectors for cancer gene therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11731024     DOI: 10.1016/s0169-409x(01)00225-3

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  13 in total

1.  Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours.

Authors:  Johanne Seguin; Céline Nicolazzi; Nathalie Mignet; Daniel Scherman; Guy G Chabot
Journal:  Tumour Biol       Date:  2012-06-07

2.  Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein.

Authors:  Natalya Belousova; Valentina Krendelchtchikova; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

3.  Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop.

Authors:  J Woraratanadharm; S Rubinchik; H Yu; F Fan; S M Morrow; J Y Dong
Journal:  Gene Ther       Date:  2004-09       Impact factor: 5.250

Review 4.  Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.

Authors:  Ethlinn V B van Gaal; Wim E Hennink; Daan J A Crommelin; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

5.  Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.

Authors:  Devanand Sarkar; Zao-Zhong Su; Nicolaq Vozhilla; Eun Sook Park; Pankaj Gupta; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

6.  Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.

Authors:  Hideaki Miyake; Kazuki Yamanaka; Mototsugu Muramaki; Isao Hara; Martin E Gleave
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

Review 7.  Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Authors:  M A Witlox; M L Lamfers; P I J M Wuisman; D T Curiel; G P Siegal
Journal:  Bone       Date:  2006-12-26       Impact factor: 4.398

8.  Transcriptional control of viral gene therapy by cisplatin.

Authors:  James O Park; Carlos A Lopez; Vinay K Gupta; Charles K Brown; Helena J Mauceri; Thomas E Darga; Abdullah Manan; Samuel Hellman; Mitchell C Posner; Donald W Kufe; Ralph R Weichselbaum
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

9.  The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells.

Authors:  Jun Wan; Jinben Ma; Ju Mei; Genfa Shan
Journal:  J Exp Clin Cancer Res       Date:  2009-12-10

10.  Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo.

Authors:  Xiao Li; Yan Liu; Zhongmei Wen; Chang Li; Huijun Lu; Mingyao Tian; Kuoshi Jin; Lili Sun; Pegn Gao; Encheng Yang; Xiaohong Xu; Shifu Kan; Zhuoyue Wang; Yuhang Wang; Ningyi Jin
Journal:  Mol Cancer       Date:  2010-01-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.